Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Videos
Pittcon 2015 - Be in Your Element ...
Video 1: DNA Nanoswitch Protocol – Intro...Repurposing Approaches for Rare and Negl...What is LabTube?...

Featured Products
Featured Product - Release & Stability Testing
Release & Stability Testing

Webcasts
Webcasts - Accelerate Your Research With Tecan´s New Multimode Microplate Reader Platform!Accelerate Your Research With Tecan´s New Multimode Microplate Reader Platform!
In this webinar, solutions will be presented for fast DNA quantification, single cell counting and viability analysis, and automating long-term live kinetic cell assays.
Webcasts - Balancing Leverage with Stewardship of a Corporate Compound CollectionBalancing Leverage with Stewardship of a Corporate Compound Collection
Rose Gonzales, Pfizer Global R&D, speaking at Drug Discovery and Development 2014

Market Reports
Immunoassay Auto Trends 2014
HTStec

This report comprehensively documents current practices and preferences in immunoassays and to understand future user requirements, particularly with respect to immunoassay automation.
Gene Expression Analysis Market by Technology, Consumables, Services & Applications - Global Forecast to 2018
MarketsandMarkets

Over the years, the gene expression analysis market, comprising of instruments, consumables, and services, has witnessed various technological advancements. These advancements have led to a growth in the number of gene expression applications.
Epigenetic Modification Screening Trends 2014
HTStec

This market report summarizes the results of HTStec’s 3nd industry-wide global web-based benchmarking survey on epigenetic modification screening carried out in May 2014.
Multi-Mode Microplate Reader Trends 2013
HTStec

This market report summarizes the results of HTStec’s 4th industry-wide global web-based benchmarking survey on multi-mode microplate readers carried out in September 2013.
GPCR Screening & Profiling Trends 2013
HTSTec

This market report summarizes the results of HTStec’s 5th industry-wide global web-based benchmarking survey on GPCR screening and profiling carried out in August 2013.
China Pharmaceutical Market Outlook
Global Data

The report details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity
GBI Research

The report examines the reasons why the pharmaceutical industry is looking for improvements in efficiency whilst acknowledging that pharmaceutical R&D remains a long and risky process. It looks in detail at precompetitive research and evaluates how the industry is pulling together to research solutions to problems that are common to all companies.
Drug Discovery and Development Market in Asia
Global Data

The report provides key data, information and analysis of the major trends and issues affecting the drug discovery and development market in seven major countries in Asia, namely China, India, Russia, Japan, Singapore, Taiwan and South Korea.
Biopharmaceutical Manufacturing in India, China and South Korea
GBI Research

The report provides an analysis of biopharmaceuticals approved in 2010 and 2011, operating dynamics in the biopharmaceutical industry, the current scenario in biopharmaceutical manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals, and forecasts to 2016 for India, China, South Korea and the global market.
Outsourced Ion Channel Testing Trends 2013
HTStec

HTStec's Outsourced Ion Channel Testing Trends 2013 report was published on 3 May 2013. This 58 page market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on outsourced ion channel testing carried out in April 2013.
Scientific News
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Paramedics May be First Line of Treatment for Stroke
NIH study demonstrates feasibility of getting drugs to stroke patients faster.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Early Blood Glucose Control Lengthens Life in People with Type 1 Diabetes
Reductions in diabetes complications resulting from tight glucose control translate into longer lifespans.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Business News
Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment
BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.
Alizé Pharma Launches Phase II Clinical Trial of AZP-531 in Prader-Willi Syndrome
Results are expected to be available by mid-2016.
Liberia-U.S. Clinical Research Partnership Opens Trial to Test Ebola Treatments
Initial study will evaluate experimental drug cocktail ZMapp.
TxCell to Present at ROTH Capital Partners Investor Conference in US
TxCell invited to speak at largest US meeting for investors in emerging growth companies.
CMXC Announces Results of Preliminary Analysis of Metabolomic Assays
Analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.
Ipsen Enters Into Option Agreement to Acquire Canbex Therapeutics
Canbex lead candidate for treating spasticity multiple sclerosis has successfully completed Phase I.
Shire Acquires Meritage Pharma
Transaction adds Phase 3-ready rare GI disease product to strong pipeline.
Bristol-Myers Squibb to Expand its Immuno-Oncology Pipeline
Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program.
Baxter Announces Baxalta as the Name of the New Global Biopharmaceutical Company
Separation into two publicly traded companies remains on track for mid-2015.
NewLink Announces Clinical Development Milestone Achieved with Merck
$20 million milestone payment.

Events
Clinical Trial Supply New Engl
10 Mar 2015
Clinical Trial Supply New Engl ...
More information
Pharmaceutical Compliance Chin
16 Mar 2015
Pharmaceutical Compliance Chin ...
More information
Pharmaceutical Compliance
23 Mar 2015
Pharmaceutical Compliance ...
More information
Paediatric Clinical Trials
25 Mar 2015
Paediatric Clinical Trials ...
More information

ePosters
Direct Targets Identification of a Bioactive Compound
Charnwood Molecular, Hybrigenics services SAS

Identifying protein partners of a small bioactive molecule is of great
interest in many aspects of life sciences and specifically in the drug
discovery and development process cycle. It is a support to (i) decipher
the mechanism of action after for example a “High Content” screening,
(ii) study “off-target” effects, (iii) adjust therapeutic indications and
clinical regimens of a drug and (iv) consider drug repositioning.
Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"
UCD Schools of Biomolecular and Biomedical Sciences, UCD Conway Institute, University College Dublin, Dublin, Ireland ////GADEA Grupo Farmacéutico, Parque Tecnologico de Boecillo, Boecillo, Valladolid

3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.
Automated detection and control of controlled substances
Scitegrity Limited

Scitegrity, in conjunction with the Pistoia Alliance and a number of pharmaceutical companies, have developed Controlled Substances Squared to scan large chemical libraries (millions of compounds) and determine whether a compound is considered as controlled in a selected country.
Antioxidant and Free Radicals Scavenging Activity of Biomolecules: Hydroxamic Acids
School of Study in Chemistry, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh, India

In the present poster attention is focused towards the investigation of antioxidant and free radicals scavenging activity of N-aryl substituted hydroxamic acids by DPPH method which is based on the reduction of alcoholic DPPH solutions in presence of a hydrogen donating antioxidant, hydroxamic acids.
Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
1Cisbio Bioassays Codolet, France | 2CRCM, CNRS UMR7258, INSERM U1068, AMU UM105, Institut Paoli-Calmettes, Marseille, France | 3AFMB, UMR7257, Univ. Aix Marseille-CNR

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

Characterization of Proteins and Protein Self Association (Oligomerization) with SEC-MALS
Malvern Instruments Ltd

In this poster, a series of proteins and their oligomers were characterized using SEC-MALS with UV and RI detection. The monomer molecular weights are measured and compared with those from column calibration. The molecular weights of their oligomers are also compared with column calibration and the differences explored.
High Throughput Screening in the European Lead Factory
Pivot Park Screening Centre

This paper describes workflows that have been implemented at the screening centre of the European Lead Factory and presents screening statistics on the first 18 months of operation.
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
(1)Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.
Mixtures Analysis of Complex Mixtures
Mestrelab Research

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.
Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
(1) Molecular Sensing, Inc., Nashville, Tennessee, USA, (2) AstraZeneca Discovery Sciences, Mölndal, Sweden, (3) AstraZeneca CVMD iMED, Mölndal, Sweden

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds
Application Notes
Cellular Dopamine and Intracellular Calcium Signaling Using the Next Generation HTS Microplate Reader
BMG Labtech

Two cell-based signaling assays from Invitrogen, Fluo-4 Direct™ Calcium Assay and Tango™-bla U2OS GPCR Assay, were performed on the PHERAstar FS HTS instrument. The PHERAstar FS has several unique features that enhance the performance of these assays including direct optic bottom reading, high resolution cell layer scanning, injection at the point of measurement and dual emission detection.
Reaction Optimisation and Large Scale Synthesis
Syrris Ltd

A major benefit of flow chemistry is the ease and consistency of reaction scale up. In a flow reactor, high quality, reproducible mixing, excellent temperature control and superheating are maintained when increasing reaction volume.
Automated Turnkey Solubility and Permeability Assays
Molecular Devices

Millipore Corporation and Molecular Devices have partnered to provide platforms for solubility and permeability screening. The objective is to create automation-compatible 96- and 384-based systems with pre-validated methods, devices and analysis that can be run manually or in conjunction with standard laboratory automation.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters